Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 10:06 p.m.

    📋 Karuna Therapeutics, Inc. (KRTX) - Financial Results

    Filing Date: 2022-08-08

    Accepted: 2022-08-08 06:50:05

    Event Type: Financial Results

    Event Details:

    Karuna Therapeutics (was acquised by Bristol Myers Squibb (NYSE: BMY) on 18/03/2024) (KRTX) Reports Q3 2022 Financial Results Karuna Therapeutics (was acquised by Bristol Myers Squibb (NYSE: BMY) on 18/03/2024) (KRTX) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 5278
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 407414
      • expected in the first quarter of 2023

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations 34.53K 123.65K $-89.11K -72.07%
    Other Income Loss Net Interest Income 106.00 727.00 $-621.00 -85.42%
    Impairment Loss On Rightofuse Assets Total Other Income Expense 115.00 1.01K $-898.00 -88.65%
    Impairment Loss On Rightofuse Assets Net Loss Per Share 1.17 4.13 $-2.96 -71.67%
    Loss from Operations 65.05K 34.53K $30.52K +88.39%
    Interest Income 490.00 106.00 $384.00 +362.26%
    Net Loss 64.42K 34.42K $30.00K +87.17%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Karuna Therapeutics (was acquised by Bristol Myers Squibb (NYSE: BMY) on 18/03/2024)
    • CIK: 0001771917
    • Ticker Symbol: KRTX
    • Period End Date: 2022-08-08
    • Document Type: 8-K

Search

News categories